Press Releases

Featured

Draig Therapeutics Closes Oversubscribed $65 Million Series B to Accelerate Development of Highly Specific AMPA and GABAA Receptor Modulators in Neuropsychiatric Disorders

Read More
Featured

Draig Therapeutics Presents New Phase 1 Data Demonstrating Safety, Tolerability, Pulsatile PK and Target Engagement by DT-101, a Novel AMPA Receptor Potentiator, at ASCP Annual Meeting

View PDF
Featured

Draig Therapeutics to Present at the American Society for Clinical Psychopharmacology (ASCP) Annual Meeting

View PDF

Draig Therapeutics to Participate in the Stifel 2026 Virtual CNS Forum

View PDF

Draig Therapeutics Appoints Seasoned Neuroscience Leader Ivana Magovčević-Liebisch as President and Chief Executive Officer

View PDF

Publications

ASCP Poster Presentation: DT-101 – A Novel AMPAR PAM Demonstrates Favorable Tolerability and Functional Biomarkers in Phase 1 Healthy Volunteer Trial

View PDF

ASCP Poster Presentation: Magnetoencephalography (MEG) in a First-in-Human Trial toDemonstrate the Functional Consequences of Target Engagement by DT-101,a Novel AMPA Receptor Positive Allosteric Modulator

View PDF

Events

Key Literature

  • DT-101

AMPA receptor modulation in depression: from molecular mechanisms of plasticity to therapeutic translation 

Wojciech Ziemichód, Natalia Kajka, Klaudia Kister, Karolina Kasprzak, Kaja Karakuła, and Dariusz Juchnowicz

View PDF
  • DT-101

Brain Neuroplasticity Mechanisms in Psychiatric Illnesses and in the Development of Novel Treatments

Patricio O'Donnell, Amit Etkin, and Husseini Manji

View More
  • DT-101

Synaptic priming: a framework for pharmacotherapy in depression

Kyle A. Browna, Musa I. Ajibolaa, Gustavo C. Medeirosa, and Todd D. Goulda

View PDF
  • DT-101

All roads lead to glutamate: NMDA and AMPA receptors as targets for rapid-acting antidepressants 

Florian Freudenberg, Christine Reif-Leonhard, Gerard R. Dawson, Ruth M. McKernan, and Andreas Reif

View PDF
  • DT-201

Negative allosteric modulation of GABAARs at α5 subunit-containing benzodiazepine sites reverses stress-induced anhedonia and weakened synaptic function in mice

Timothy A. Troppoli, Panos Zanos, Polymnia Georgiou, Todd D. Gould, Uwe Rudolph, and Scott M. Thompson

View PDF

The Future of Brain Health Starts Here

Whether you're a patient, caregiver, researcher, investor, or member of the press, we'd love to hear from you.

Contact Us